4.75

6.26% 0.28

Pre-market: 4.83 0.08 +1.68%

Atyr Pharma Inc (ATYR)

Overview News Price History Discussions Forecast

Atyr Pharma Inc stock is traded at $4.75, with a volume of 2.46M. It is up +6.26% in the last 24 hours and up +31.94% over the past month. aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Previous Close:

$4.47

Open:

$4.505

24h Volume:

2.46M

Relative Volume:

1.71

Market Cap:

$422.75M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+26.67%

1M Performance:

+31.94%

6M Performance:

+33.43%

1Y Performance:

+0.00%

1-Day Range:

$4.365

$4.83

1-Week Range:

$3.73

$4.83

52-Week Range:

$1.42

$4.83

Atyr Pharma Inc Stock (ATYR) Company Profile

Name

Atyr Pharma Inc

Sector

Healthcare (1166)

Industry

Biotechnology (665)

Phone

(858) 731-8389

Address

10240 SORRENTO VALLEY ROAD, SAN DIEGO

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

ATYR's Discussions on Twitter

Compare ATYR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATYR Atyr Pharma Inc	4.75	344.45M	0	0	0	0.00
ONC Beone Medicines Ltd Adr	245.93	25.76B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	445.43	114.53B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.415	40.54M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	84.10	6.44B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.81	65.13B	14.09B	4.50B	2.96B	39.28

Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-18-25	Initiated	Leerink Partners	Outperform
Jan-06-25	Initiated	Cantor Fitzgerald	Overweight
Oct-04-24	Initiated	Wells Fargo	Overweight
Sep-05-24	Initiated	Jefferies	Buy
Jul-05-23	Downgrade	Oppenheimer	Outperform → Perform
Oct-12-21	Initiated	RBC Capital Mkts	Outperform
Sep-21-21	Initiated	Piper Sandler	Overweight
May-10-21	Initiated	Laidlaw	Buy
Aug-17-20	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-04-20	Initiated	ROTH Capital	Buy
Mar-02-20	Initiated	Oppenheimer	Outperform
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-07-17	Initiated	Piper Jaffray	Overweight
Dec-13-16	Downgrade	JP Morgan	Overweight → Neutral
Dec-16-15	Initiated	Citigroup	Neutral
Jun-01-15	Initiated	Citigroup	Buy
Jun-01-15	Initiated	JP Morgan	Overweight

View All

Atyr Pharma Inc Stock (ATYR) Latest News

Jun 02, 2025

aTyr Pharma (ATYR) Scheduled for Key Presentation in New York | - GuruFocus

Jun 02, 2025

aTyr Pharma stock soars to 52-week high of $4.66 By Investing.com - Investing.com Nigeria

Jun 02, 2025

May 31, 2025

182,625 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Bought by Northern Trust Corp - Defense World

May 31, 2025

May 29, 2025

Atyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

May 29, 2025

May 27, 2025

High Growth Tech Stocks in the US to Watch This May 2025 - Yahoo Finance

May 27, 2025

May 26, 2025

Group One Trading LLC Takes $26,000 Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World

May 26, 2025

Jane Street Group LLC Invests $720,000 in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World

May 26, 2025

May 24, 2025

aTyr Pharma’s SWOT analysis: biotech firm’s stock poised for potential breakthrough - Investing.com India

May 24, 2025

aTyr Pharma’s SWOT analysis: biotech firm’s stock poised for potential breakthrough By Investing.com - Investing.com South Africa

May 24, 2025

May 21, 2025